Option chain shows key data for Redhill Biopharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Redhill Biopharma.

Redhill Biopharma (NASDAQ:RDHL) Stock, Option Chain

Redhill Biopharma

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

Screenshot 2024-12-05 at 6.50.09 PM

News

RDHL

Supreme Court Of New York Awards RedHill Biopharma Approx. $8 Million Plus Costs In Breach Of Contract Lawsuit

Screenshot 2024-10-14 at 5.39.36 PM

Biotech

General

RedHill Biopharma Secures U.S. Government Funding Through BARDA To Advance Opaganib For Ebola Treatment

Screenshot 2024-08-22 at 5.32.58 PM

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma Ltd

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>)</h3>
<ul>
<li>Dividend Yield: 7.08%</li>
<li>Wells Fargo analyst Connor Siversky assumed an Overweight rating and raised the price target from $40 to $43 on Oct. 1. This analyst has an accuracy rate of 65%.</li>
<li>Truist Securities analyst Michael Lewis maintained a Hold rating and raised the price target from $33 to $39 on Sept. 4. This analyst has an accuracy rate of 71%.</li>
<li>Recent News: On Oct. 30, Omega Healthcare Investors reported better-than-expected third-quarter financial results and raised its FY24 adjusted FFO guidance.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1">latest OHI news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="910" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085216/image-188.png" alt="" class="wp-image-704244" style="width:688px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085216/image-188.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085216/image-188-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085216/image-188-768x709.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<h3 class="wp-block-heading">OUTFRONT Media Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUT#NYSE">OUT</a>)</h3>
<ul>
<li>Dividend Yield: 6.60%</li>
<li>Morgan Stanley analyst Benjamin Swinburne maintained an Equal-Weight rating and raised the price target from $17 to $18 on Dec. 18. This analyst has an accuracy rate of 76%.</li>
<li>Barrington Research analyst James Goss maintained an Outperform rating with a price target of $21 on Nov. 13. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Nov. 12, Outfront Media posted mixed quarterly results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1">latest OUT news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="892" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085251/image-189.png" alt="" class="wp-image-704245" style="width:575px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085251/image-189.png 892w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085251/image-189-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085251/image-189-768x717.png 768w" sizes="(max-width: 892px) 100vw, 892px" /></a></figure>
<h3 class="wp-block-heading">LTC Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTC#NYSE">LTC</a>)</h3>
<ul>
<li>Dividend Yield: 6.50%</li>
<li>Wells Fargo analyst Connor Siversky assumed an Equal-Weight rating and raised the price target from $36 to $37 on Oct. 1. This analyst has an accuracy rate of 65%.</li>
<li>Wedbush analyst Richard Anderson reiterated an Outperform rating and a price target of $40 on Sept. 20. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: LTC named Wendy Simpson Executive Chairman Of The Board, promoted Pam Kessler and Clint Malin to co-Chief Executive Officers, and Cece Chikhale Tto Chief Financial Officer, effective Dec. 31.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"> trend in LTC stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="898" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085334/image-190.png" alt="" class="wp-image-704248" style="width:623px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085334/image-190.png 898w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085334/image-190-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085334/image-190-768x716.png 768w" sizes="(max-width: 898px) 100vw, 898px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Wall Street's Most Accurate Analysts Spotlight On 3 Real Estate Stocks Delivering High-Dividend Yields

XBIT

Trading Halt: Halted at 8:55:10 a.m. ET - Trading Halt: Halt News Pending

Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) shares are trading higher premarket on Monday. On Sunday, the company disclosed securing around <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42639115/faraday-future-secures-30-million-financing-to-strengthen-the-companys-core-business-and-continued" rel="noreferrer noopener">$30 million in cash financing commitments</a>.
The financing comprises $7.5 million pre-funded in the fourth quarter of 2024 and $22.5 million in new cash commitments structured as unsecured convertible notes and warrants.
The Convertible Notes have a conversion price of $1.16 per share, while the Warrants are exercisable at $1.392 per share, subject to adjustments.
The underlying shares are currently unregistered and not immediately tradable. The financing remains subject to customary closing conditions.
The funds will support the development of Faraday X (FX). The company is targeting the mainstream U.S. EV market with plans to deliver its first two FX prototype mules to Los Angeles later this month.
Product development and testing will commence at the company's Hanford, CA, manufacturing facility.
FFIE CEO Matthias Aydt said, "The new funding lays a solid foundation for both FF and its new brand as the Company approaches the end of 2024 and enters the new year."
"I am optimistic about the opportunities that this new funding will bring, including supporting the ongoing production of our FF 91 2.0 and the growth of the FX brand."
Last month, the company announced the launch of a development phase after its first FX <a target="_blank" href="https://www.benzinga.com/news/global/24/11/42092678/whats-going-on-with-faraday-future-intelligent-electric-stock" rel="noreferrer noopener">prototypes&nbsp;arrived at its headquarters</a>.
Price Action: FFIE shares are up 12.07% at $1.3000 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41541997/revving-up-in-the-middle-east-faradays-new-uae-headquarters-solidifies-ev-expansion-strategy" target="_blank" rel="noreferrer noopener">Revving Up In The Middle East: Faraday's New UAE Headquarters Solidifies EV Expansion Strategy</a></li>
</ul>
Photo Courtesy of Faraday Future Intelligent Electric

Equities

Financing

Small Cap

Movers

FFIE

Why Is Faraday Future Intelligent Electric Trading Higher On Monday?

IKNA

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

WIIM

AILE

iLearningEngines shares are trading lower after the company announced it voluntarily filed for Chapter 11 Bankruptcy,

RBC Capital analyst Gregory Renza reiterates Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) with a Outperform and maintains $68 price target.

Reiteration

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

RBC Capital Reiterates Outperform on Jasper Therapeutics, Maintains $68 Price Target

Truist Securities analyst Michael Lewis maintains National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Hold and lowers the price target from $78 to $72.

Truist Securities Maintains Hold on National Health Investors, Lowers Price Target to $72

RAPT

RAPT Therapeutics shares are trading higher after the company announced a partnership with Shanghai Jemincare Pharmaceutical for an exclusive license agreement to develop and commercialize RPT904, a novel anti-IgE monoclonal antibody.

Macro Economic Events

Econ #s

Economics

USA Core Durable Goods Orders (MoM) For November -0.1% Vs 0.2% Prior

RBC Capital analyst Steven Shemesh reiterates Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) with a Outperform and maintains $130 price target.

OLLI

RBC Capital Reiterates Outperform on Ollie's Bargain Outlet, Maintains $130 Price Target

USA Durables Excluding Defense (MoM) For November -0.3% Vs 0.5% Prior

U.S. stocks settled higher on Friday, with the Dow Jones index surging almost 500 points during the session.
Even as the major indices recorded gains on Friday, all three averages fell last week. The Dow dipped around 2.3% to record its third losing week in a row. The S&amp;P 500 declined about 2%, while the Nasdaq Composite fell around 1.8% last week.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Jay McCanless
<ul>
<li>Analyst Firm: Wedbush</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Reiterated a Neutral rating on Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) with a price target of $164 on Dec. 19. This analyst sees around 19% upside in the stock.</li>
<li>Recent News: On Dec. 18, Lennar reported worse-than-expected fourth-quarter financial results.</li>
</ul>
Analyst: Andres Sheppard
<ul>
<li>Analyst Firm: Cantor Fitzgerald</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Maintained an Overweight rating on Archer Aviation Inc. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) and raised the price target from $10 to $13 on Dec. 18. This analyst sees around 34% upside in the stock.</li>
<li>Recent News: On Dec. 12, Archer announced a partnership with Anduril to develop hybrid VTOL military aircraft and reported raising an additional $430 million in equity capital.</li>
</ul>
Analyst: Doug Anmuth 
<ul>
<li>Analyst Firm: JP Morgan</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained an Overweight rating on Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and raised the price target from $250 to $280 on Dec. 18. This analyst sees around 24% upside in the stock.</li>
<li>Recent News: Amid peak holiday shopping, Amazon.com recently announced that its operations will remain unaffected despite a strike initiated by workers at seven of its U.S. facilities.</li>
</ul>
Analyst: Jessica Reif Ehrlich
<ul>
<li>Analyst Firm: B of A Securities</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Buy rating on Fox Corporation &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) and increased the price target from $50 to $55 on Dec. 18. This analyst sees around 11% surge in the stock.</li>
<li>Recent News: On Dec. 17, Fox announced its digital presence reached 2.4 billion total multiplatform views in November.</li>
</ul>
Analyst: Aaron Rakers
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained an Overweight rating on Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) and decreased the price target from $175 to $140 on Dec. 19. This analyst sees around 55% upside in the stock.</li>
<li>Recent News: On Dec. 18, Micron reported first-quarter revenue of $8.71 billion, missing the consensus estimate of $8.72 billion.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Long Ideas

ACHR

AMZN

FOXA

This Analyst With 86% Accuracy Rate Sees Around 24% Upside In Amazon.com - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

Macro Notification

USA Durable Goods Orders (MoM) For November -1.1% Vs 0.3% Prior

Truist Securities analyst Jamie Cook reiterates AGCO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>) with a Buy and lowers the price target from $116 to $109.

AGCO

Truist Securities Reiterates Buy on AGCO, Lowers Price Target to $109

GTBP

GT Biopharma shares are trading higher. Roth MKM initiated coverage on the stock with a Buy rating and set its price target at $11.

Agnico Eagle Mines Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AEM#TSX">AEM</a>)&nbsp;("Agnico Eagle") announced today that it has completed a transaction with ONGold Resources Ltd. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/ONAU#TSXV">ONAU</a>) ("ONGold") which resulted in Agnico Eagle acquiring 8,700,000 common shares ("Common Shares") of ONGold.
On November 25, 2024, Yamana Gold Ontario Inc. ("Yamana"), a wholly-owned subsidiary of Agnico Eagle, and 10215825 Manitoba Ltd. (the "Buyer"), a wholly-owned subsidiary of ONGold, entered into an asset purchase agreement, pursuant to which the Buyer agreed to purchase certain assets from Yamana in exchange for, among other things, the issuance of Common Shares to Agnico Eagle (the "Transaction"). On December 20, 2024, the Transaction was completed, which resulted in Agnico Eagle acquiring 8,700,000 Common Shares.
Agnico Eagle currently owns 8,700,000 Common Shares, representing approximately 15.0% of the issued and outstanding Common Shares on a non-diluted basis. Prior to the closing of the Transaction, Agnico Eagle did not own any Common Shares.
In connection with closing of the Transaction, Agnico Eagle and ONGold entered into an investor rights agreement pursuant to which ONGold granted Agnico Eagle certain rights, provided that Agnico Eagle maintains certain ownership thresholds in ONGold, including: (a) the right to participate in equity financings and top-up its holdings in relation to dilutive issuances in order to maintain its pro rata ownership interest in ONGold at the time of such financing or acquire up to a 19.99% ownership interest in ONGold; and (b) the right (which Agnico Eagle has no present intention of exercising) to nominate one person (and in the case of an increase in the size of the board of directors of ONGold to eight or more directors, two persons) to the board of directors of ONGold.

TSX:AEM

TSXV:ONAU

Agnico Eagle Acquires 8.7M Shares Of ONGold, Secures 15% Stake; Granted Rights To Boost Holdings Up To 19.99%

<a href="https://www.globenewswire.com/Tracker?data=3IO2gUzW7Cw-Q-FQqDZQbgLiiQ15aDUo_4CXaPHofKgijz46bDoLlvDH-Fk4Z6ygMULR9uH-DRpTw3HQ5bSqk1TB6EK6oPj8GjxiZBN4BQc=">OptimizeRx Corp.</a> (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that William J. Febbo, Chief Executive Officer (CEO) and Board Member, will be departing the Company, effective as of December 31, 2024, to pursue other opportunities. Mr. Febbo will provide the Company with advisory services through March 31, 2025. The Company's Board of Directors has retained a search firm to assist in this transition.

Management

OPRX

OptimizeRx CEO William Febbo To Depart, Announces Appointment Of Stephen Silvestro As Interim CEO, Effective As Of December 31, 2024

Prestige Wealth shares are trading higher after the company announced it regained Nasdaq Compliance.

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>). &#8220;That business is <a href="https://www.benzinga.com/quote/ANET/analyst-ratings">smoking hot,&#8221; he added</a>.
On Dec. 17, Morgan Stanley analyst Meta Marshall maintained Arista Networks with an Overweight and raised the price target from $102.5 to $118.
Cramer said Under Armour, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UA#NYSE">UA</a>) is a &#8220;great spec.&#8221; However, he recommended being careful.
On Dec. 12, Under Armor reiterated its FY25 guidance.
When asked about Texas Pacific Land Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPL#NYSE">TPL</a>), he said, &#8220;We have liked it, but it's now gone up so much. I've got to tell you, I want to hold off.&#8221;
On Nov. 6, Texas Pacific Land posted weaker-than-expected quarterly sales.
Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) is a &#8220;terrific&#8221; stock, Cramer said. "I like the LNG market now that we have President-elect Trump coming in because he's pro LNG.&#8221;
On Oct. 31, Cheniere Energy reported better-than-expected third-quarter financial results and raised its FY24 adjusted EBITDA guidance. Cheniere Energy reported quarterly earnings of $3.93 per share which beat the analyst consensus estimate of $1.87 per share. The company reported quarterly sales of $3.763 billion which beat the analyst consensus estimate of $3.729 billion.
Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) is a buy, the &#8220;Mad Money&#8221; host said.
Wells Fargo Bank lowered its prime rate to 7.50% from 7.75%, effective Dec. 19, 2024.
&#8220;These are really good companies, you have to buy them when they're low,&#8221; Cramer said when asked about CSX Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>).
CSX will release fourth quarter financial and operating results after the closing bell on Thursday, Jan. 23, 2025.
&#8220;You want to hold on to Eaton Corporation plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>). You know, Eaton is a buy and hold story,&#8221; Cramer said. &#8220;Do not sell, own.&#8221;
On Dec. 9, Citigroup analyst Andrew Kaplowitz maintained Eaton with a Buy and raised the price target from $394 to $440.
Price Action:
<ul>
<li>Cheniere Energy shares gained 1.4% to settle at $208.89 on Friday.</li>
<li>Arista shares rose 3.4% to close at $112.81 during the session.</li>
<li>Eaton shares rose 0.7% to settle at $338.12.</li>
<li>Texas Pacific Land shares gained 3.4% to settle at $1,133.12 on Friday.</li>
<li>Under Armour shares gained 2.9% to $7.78 on Friday.</li>
<li>Wells Fargo shares gained 2.2% to settle at $70.34 on Friday.</li>
<li>CSX shares gained 0.9% to close at $31.85.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/author/avi-kapoor">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Media

ANET

Jim Cramer Says Under Armour Is A 'Great Spec,' Recommends Buying This Big Bank Stock

CN (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CNR#TSX">CNR</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNI#NYSE">CNI</a>) announced today that its new four-year tentative collective agreements with Unifor were formally ratified by employees on Sunday, December 22, 2024. The union represents approximately 3,300 employees at CN in Canada, working in different mechanical, clerical, and intermodal functions, all covered by multiple collective agreements.

Contracts

TSX:CNR

CN Announces That Its New 4-Year Tentative Collective Agreements With Unifor Were Formally Ratified By Employees On Sunday, December 22, 2024

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma Ltd. has announced the postponement of its Annual General Meeting of Shareholder...

RedHill Biopharma Postpones Shareholder Meeting

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma Ltd. recently held its Annual General Meeting, with shareholders approving all p...

RedHill Biopharma Shareholders Approve Key Resolutions

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma Ltd. has announced a new U.S. patent for Opaganib, targeting the treatment of CO...

RedHill Biopharma Secures Opaganib COVID-19 Patent

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma has renewed its contract with Medi-Cal, ensuring Talicia's continued availabilit...

RedHill Biopharma Secures Talicia's Position in Medi-Cal

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma has secured funding from the U.S. government's BARDA to advance opaganib, a nove...

RedHill Biopharma Partners with BARDA for Ebola Treatment

RedHill Biopharma (RDHL) announced the signing of a collaborative research agreement with Duke University School of Medicine outlining plans for mu...

RedHill Biopharma signs research pact with Duke University School of Medicine

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma has announced a collaboration with Duke University School of Medicine to test th...

RedHill Biopharma and Duke Collaborate on Opaganib Development

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma has been selected to present its promising drug, Opaganib, at a U.S. government ...

RedHill Biopharma to Present Opaganib at U.S. Defense Conference

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma has secured a favorable judgment of approximately $8 million plus costs from the...

RedHill Biopharma Wins $8 Million Court Judgment

RedHill Biopharma (RDHL) announced that the Company has been awarded approximately $8 million, plus costs in a summary judgment by the Supreme Cour...

RedHill Biopharma awarded judgement of approx $8M by NY Supreme Court

Press Releases

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

Comments

Redhill Biopharma

Redhill Biopharma (RDHL) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga